We are an iconic provider of hospital-based healthcare, striving to deliver an exceptional standard of care
We comprise several hospitals, health centres, a nationally accredited education provider and a world-class research institute
We are a nationally accredited, hospital-based Registered Training Organisation - the only one of its kind in Queensland
We are part of a collaborative research institute with The University of Queensland and founding partner of the Translational Research Institute
Health . Education . Research . Foundation
Brisbane landmarks will turn green tonight for International Stuttering Awareness Day as we shine a light on the chronic communication disorder. Stuttering impacts around one per cent of the population and has no cure.
Mater Senior Speech Pathologist Amanda Lyons said stuttering can affect people in many ways and can impact educational and employment opportunities.
“Current research suggests that this complex condition is caused by both genetic and neurological factors,” Lucy said.
Mater Health has a long history of providing treatment to people who stutter, commencing in the late 1970s.
“Our weekly Fluency Skills Group has been running since the early 1980s,” Lucy said.
“Adults and young adults who stutter can attend the Mater-ACU Fluency Clinic, while children who stutter can receive treatment at Mater Health & Wellness Clinic.”
Mater Speech Pathology maintains strong links with the Australian Speak Easy Association.
Tonight in Brisbane the Story Bridge, Victoria Bridge and Reddacliff Place sculptures will light up in green to recognition of the day.
07 3163 8111
07 3163 6142
The Annual Mater Research Awards and Young Investigator Symposium has been held in Brisbane this week recognising the significant contribution of seasoned and ...
A keen interest in improving the quality of blood management in the acute healthcare setting at Mater has won Alana Delaforce the Young Investigator Award at the ...
Some of the smallest people at Mater are learning how to make a big impact on the environment through a unique hands on learning program.
A new drug, yet to be approved by the Therapeutic Goods Administration, is giving a small group of chronic Cystic Fibrosis (CF) patients at Mater a second chance at life.